Towa Pharmaceutical Co., Ltd. (TYO:4553)
Japan · Delayed Price · Currency is JPY 3,950.00
+90.00 (2.33%)
May 29, 2026, 3:30 PM JST
Towa Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 13,165 | 26,330 | 24,459 | 4,605 | 22,246 |
Depreciation & Amortization | 22,837 | 20,099 | 17,888 | 19,409 | 10,954 |
Loss (Gain) From Sale of Assets | 14,837 | -218 | -225 | 478 | -96 |
Loss (Gain) From Sale of Investments | -24 | 3 | -18 | 19 | 5 |
Other Operating Activities | -8,267 | -10,046 | -1,036 | -5,910 | -4,437 |
Change in Accounts Receivable | -792 | -565 | -15,523 | -1,592 | 441 |
Change in Inventory | -13,790 | -7,204 | -6,288 | -18,496 | -7,950 |
Change in Accounts Payable | 2,952 | 3,687 | -10,509 | 6,554 | 3,675 |
Change in Other Net Operating Assets | -489 | -8,685 | -536 | -2,523 | -2,709 |
Operating Cash Flow | 30,429 | 23,401 | 8,212 | 2,544 | 22,129 |
Operating Cash Flow Growth | 30.03% | 184.96% | 222.80% | -88.50% | 84.28% |
Capital Expenditures | -22,277 | -28,736 | -37,851 | -28,731 | -11,140 |
Sale of Property, Plant & Equipment | 13 | 9 | 1 | 239 | 42 |
Cash Acquisitions | - | - | -1,570 | - | -45,405 |
Sale (Purchase) of Intangibles | -1,851 | -2,211 | -1,055 | -1,723 | -2,353 |
Investment in Securities | -1,492 | -203 | -50 | -267 | 17 |
Other Investing Activities | -53 | -146 | 131 | 198 | -220 |
Investing Cash Flow | -25,660 | -31,287 | -40,394 | -30,284 | -59,729 |
Short-Term Debt Issued | 2,081 | 1,603 | - | - | 47,135 |
Long-Term Debt Issued | 10,898 | 26,365 | 46,935 | 78,831 | 9,160 |
Total Debt Issued | 12,979 | 27,968 | 46,935 | 78,831 | 56,295 |
Short-Term Debt Repaid | - | - | -768 | -45,680 | - |
Long-Term Debt Repaid | -19,409 | -12,592 | -7,607 | -12,268 | -7,181 |
Total Debt Repaid | -19,409 | -12,592 | -8,375 | -57,948 | -7,181 |
Net Debt Issued (Repaid) | -6,430 | 15,376 | 38,560 | 20,883 | 49,114 |
Issuance of Common Stock | - | - | - | - | 21 |
Common Dividends Paid | -3,937 | -2,953 | -2,952 | -3,100 | -2,411 |
Other Financing Activities | 3,539 | 9,144 | -201 | -302 | -184 |
Financing Cash Flow | -6,828 | 21,567 | 35,407 | 17,481 | 46,540 |
Foreign Exchange Rate Adjustments | 1,410 | 1,916 | 2,167 | 1,685 | 975 |
Miscellaneous Cash Flow Adjustments | 1 | 212 | 1 | 1 | - |
Net Cash Flow | -648 | 15,809 | 5,393 | -8,573 | 9,915 |
Free Cash Flow | 8,152 | -5,335 | -29,639 | -26,187 | 10,989 |
Free Cash Flow Growth | - | - | - | - | 282.76% |
Free Cash Flow Margin | 2.98% | -2.05% | -13.00% | -12.54% | 6.64% |
Free Cash Flow Per Share | 165.60 | -108.38 | -602.17 | -532.02 | 218.36 |
Cash Interest Paid | 2,229 | 1,594 | 941 | 610 | 226 |
Cash Income Tax Paid | 8,522 | 10,889 | 1,760 | 6,285 | 4,748 |
Levered Free Cash Flow | -2,864 | -15,700 | -32,622 | -27,055 | -1,466 |
Unlevered Free Cash Flow | -1,451 | -14,683 | -32,030 | -26,658 | -1,322 |
Change in Working Capital | -12,119 | -12,767 | -32,856 | -16,057 | -6,543 |